Peak Ridge Capital

Peak Ridge Capital Group, Inc. is a private equity and venture capital firm based in Boston, Massachusetts, with additional offices in Madison, Wisconsin; San Francisco, California; Calgary, Canada; and Hamilton, Bermuda. Established in 2000, the firm specializes in growth capital investments and also manages hedge funds that focus on commodities markets, utilizing quantitative models and arbitrage trading strategies. Peak Ridge Capital seeks to co-invest in its portfolio companies and is actively involved in sectors such as agriculture, real estate, and energy within the United States. The firm aims to provide unique investment products tailored to meet the diverse expectations and objectives of its investor base.

Daniel Greene

Partner

Michael McNally

Founder and Managing Partner

Jason Rome

Operating Partner

Robert Showers

Partner

Jason Smith

President and Private Equity Partner

7 past transactions

Zurex Pharma

Series D in 2018
Zurex Pharmacy is a specialty pharmacy and medical technology company with a novel antimicrobial technology platform. Their company's mission is to develop and commercialize a portfolio of new antimicrobial products designed to prevent healthcare-acquired infections with a focus on surgical site wounds and catheter-related infections. It was founded in 2010 and is headquartered in Middleton, Wisconsin.

Zurex Pharma

Series B in 2014
Zurex Pharmacy is a specialty pharmacy and medical technology company with a novel antimicrobial technology platform. Their company's mission is to develop and commercialize a portfolio of new antimicrobial products designed to prevent healthcare-acquired infections with a focus on surgical site wounds and catheter-related infections. It was founded in 2010 and is headquartered in Middleton, Wisconsin.

Xolve

Funding Round in 2012
Xolve, Inc., a nanomaterials company, produces and supplies graphene that is used to improve the properties of various industrial plastics for use in automotive, aerospace, electronics, and other applications. It offers graphene-loaded polymer master batches, pristine graphene nanoplatelets, and exfoliated graphene. Xolve, Inc. was formerly known as Graphene Solutions, Inc. and changed its name to Xolve, Inc. in September 2010. The company was founded in 2008 and is based in Middleton, Wisconsin. As of March 31, 2016, Xolve, Inc. operates as a subsidiary of Reliance Industries Limited.

Zurex Pharma

Series A in 2012
Zurex Pharmacy is a specialty pharmacy and medical technology company with a novel antimicrobial technology platform. Their company's mission is to develop and commercialize a portfolio of new antimicrobial products designed to prevent healthcare-acquired infections with a focus on surgical site wounds and catheter-related infections. It was founded in 2010 and is headquartered in Middleton, Wisconsin.

Zurex Pharma

Seed Round in 2011
Zurex Pharmacy is a specialty pharmacy and medical technology company with a novel antimicrobial technology platform. Their company's mission is to develop and commercialize a portfolio of new antimicrobial products designed to prevent healthcare-acquired infections with a focus on surgical site wounds and catheter-related infections. It was founded in 2010 and is headquartered in Middleton, Wisconsin.

Rapid Diagnostek

Series B in 2010
Rapid Diagnostek formerly Intellignostics, has developed a patented, inexpensive, easy to use sensor appropriate for detecting bacteria, viruses, spores and disease biomarkers. Markets of opportunity include human and veterinary diagnostic, environmental, biohazard, bioterrorism, agricultural commodity, and food safety testing. Its technology offers remarkably faster and less expensive results than existing methods. Current diagnostic tests can take hours to days from the time a sample is taken to delivery of results. Rapid Diagnostek's IntelliProbe Immunosensor (IPI) platform can deliver results at the point of sampling in under 60 seconds. The sensor has performed as intended in the laboratory and the company is now developing a fully functioning device and initial assays to aggressively move towards commercialization.

Rapid Diagnostek

Series A in 2008
Rapid Diagnostek formerly Intellignostics, has developed a patented, inexpensive, easy to use sensor appropriate for detecting bacteria, viruses, spores and disease biomarkers. Markets of opportunity include human and veterinary diagnostic, environmental, biohazard, bioterrorism, agricultural commodity, and food safety testing. Its technology offers remarkably faster and less expensive results than existing methods. Current diagnostic tests can take hours to days from the time a sample is taken to delivery of results. Rapid Diagnostek's IntelliProbe Immunosensor (IPI) platform can deliver results at the point of sampling in under 60 seconds. The sensor has performed as intended in the laboratory and the company is now developing a fully functioning device and initial assays to aggressively move towards commercialization.